Bio News

• Bio News

  Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer

  2024年7月2日 3990
• Bio News

  Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations

  2024年6月24日 4080
• Bio News

  【Breaking News！】Once a Week! Novo Nordisk’s Ultra-Long-Acting Insulin Approved in China for the Treatment of Diabetes

  2024年6月24日 6400
• Bio News

  Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention

  2024年6月21日 5290
• Bio News

  Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above

  2024年6月21日 4400
• Bio News

  Day One Announces Sale of Priority Review Voucher for $108 Million

  2024年6月20日 4420
• Bio News

  Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers

  2024年6月20日 4870
• Bio News

  Ascidian Therapeutics Enters Collaboration with Roche for Discovery and Development of RNA Exon Editing Therapeutics Targeting Neurological Diseases

  2024年6月20日 4220
• Bio News

  Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)

  2024年6月15日 6040
• Bio News

  AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease

  2024年6月13日 5980